News Releases

OptimizeRx Reports Third Quarter 2022 Financial Results

November 8, 2022 at 4:01 PM EST
  • Q3 Revenue of $15.1 million, down 6% year-over-year and up 8% quarter-over-quarter
  • Gross profit increased 4% year-over-year to $9.4 million as gross margins increased from 56% to 62%
  • Generated $7.9 million in cash flow from operations during the first nine months of 2022
  • Repurchased 1.1 million shares - year to date - at an average price of $16.70 per share

ROCHESTER, Mich., Nov. 08, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended September 30, 2022. Quarterly comparisons are to the same year-ago period.

  Rolling Twelve Months Ended September 30,
Key Performance Indicators (KPIs)*   2022       2021  
Average revenue per top 20 pharmaceutical manufacturer $ 2,188,300     $ 2,516,515  
Percent of top 20 pharmaceutical manufacturers that are customers   95 %     90 %
Percent of total revenue attributable to top 20 pharmaceutical manufacturers   66 %     79 %
Net revenue retention   96 %     161 %
Revenue per average full-time employee $ 618,711     $ 740,728  

Will Febbo, OptimizeRx CEO commented, “We are seeing significant momentum off the mid-year trough, and are confident that we are gaining traction across our business in particular with our Real World Evidence (RWE) solutions. RWE is an important growth driver, and we believe it aligns well with digital trends across the life sciences industry including pharma manufacturers moving a greater percentage of their commercial spend towards omni-channel digital solutions. We believe smarter solutions - such as OptimizeRx’s RWE - will capture the lion’s share of the pharma legacy commercial dollars that are reallocated to digital. We believe executing on just the RWE opportunities we have in front of us today could position us to grow our topline by over 20% next year."

Financial Highlights

  • Revenue in the third quarter of 2022 decreased 6% to $15.1 million, from $16.1 million as compared to the same year ago period.
  • Gross profit in the third quarter of 2022 increased 4% year-over-year to $9.4 million.
  • GAAP net loss totaled $3.5 million or $(0.19) per basic and diluted share in the third quarter.
  • Non-GAAP net income in the third quarter totaled $1.3 million or $0.07 per fully diluted shares outstanding. (see definition of this non-GAAP measure and reconciliation to GAAP, below).
  • Cash, cash equivalents and short-term investments totaled $78.8 million as of September 30, 2022 as compared to $84.7 million as of December 31, 2021.

2022 Financial Outlook
Based on third quarter results, the Company is reiterating its full year financial outlook for 2022 for net revenue to be between $62 million and $68 million, representing year-over-year growth of 1% to 11%, respectively, and gross margins to be between 59% and 62%.

Conference Call
OptimizeRx management will host the presentation, followed by a question-and-answer period.

Date: Tuesday, November 8, 2022
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Web access:
Toll-free dial-in number: 1-888-999-3182
International dial-in number: 1-848-280-6330
Conference ID: 8072033

Please call the conference telephone number five minutes prior to the start time.

A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at

Definition and Use of Non-GAAP Financial Measures
This earnings release includes a presentation of non-GAAP net income and non-GAAP net income per diluted share or non-GAAP EPS, both of which are non-GAAP financial measures.

The Company defines non-GAAP net income as GAAP net income (loss) with an adjustment to add back depreciation, amortization, stock-based compensation, acquisition expenses, income or loss related to the fair value of contingent consideration, and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a diluted basis. The Company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow of the Company.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a Company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company’s core business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the Company’s own core business operating results over different periods of time.

The Company’s non-GAAP net income and non-GAAP EPS measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company’s non-GAAP net income and non-GAAP EPS are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.

The table, “Reconciliation of non-GAAP to GAAP Financial Measures,” included below, provides a reconciliation of non-GAAP net income and non-GAAP EPS for the three months ended September 30, 2022 and 2021.

Definition of Key Performance Indicators*
Top 20 pharmaceutical manufacturers: Top 20 pharmaceutical manufacturers are based on Fierce Pharma’s “The top 20 pharma companies by 2020 revenue.”

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average Full Time Employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent.

About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications. 

For more information, follow the Company on TwitterLinkedIn or visit

Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

OptimizeRx Contact

Andy D’Silva, SVP Corporate Finance
Relations Contact

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC


  September 30,
  December 31,
Current Assets      
Cash and cash equivalents $ 41,329,020     $ 84,681,770  
Short term investments   37,468,889        
Accounts receivable, net   17,813,708       24,800,585  
Prepaid expenses and other   2,722,987       5,630,655  
Total Current Assets   99,334,604       115,113,010  
Property and equipment, net   144,084       143,818  
Other Assets      
Goodwill   22,673,820       14,740,031  
Intangible assets, net   13,452,893       10,646,654  
Right of use assets, net   255,161       328,820  
Security deposits and other assets   12,859       12,859  
Total Other Assets   36,394,733       25,728,364  
TOTAL ASSETS $ 135,873,421     $ 140,985,192  
Current Liabilities      
Accounts payable – trade $ 1,000,625     $ 606,808  
Accrued expenses   1,699,558       2,902,836  
Revenue share payable   2,673,622       4,378,216  
Current portion of lease obligations   87,448       90,982  
Deferred revenue   673,214       1,389,907  
Total Current Liabilities   6,134,467       9,368,749  
Non-Current Liabilities      
Lease liabilities, net of current portion   166,751       236,726  
Total Liabilities   6,301,218       9,605,475  
Commitments and contingencies (See note 10)          
Stockholders’ Equity      
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2022 and December 31, 2021          
Common stock, $0.001 par value, 166,666,667 shares authorized, 18,261,239 issued at September 30, 2022 and 17,860,975 shares issued and outstanding at December 31, 2021   18,261       17,861  
Treasury stock   (706 )      
Additional paid-in-capital   175,920,910       166,615,514  
Accumulated deficit   (46,366,262 )     (35,253,658 )
Total Stockholders’ Equity $ 129,572,203     $ 131,379,717  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 135,873,421     $ 140,985,192  

The accompanying notes are an integral part of these condensed consolidated financial statements.


  For Three Months Ended September 30,   For Nine Months Ended September 30,
    2022       2021     2022       2021  
Net Revenue $ 15,085,504     $ 16,124,951   $ 42,795,699     $ 40,979,801  
Cost of revenues   5,664,733       7,047,832     16,283,307       17,733,400  
Gross profit   9,420,771       9,077,119     26,512,392       23,246,401  
Operating expenses              
Salaries, wages, & benefits   5,088,955       4,619,320     15,376,370       12,106,933  
Stock-based compensation   4,277,241       1,008,007     11,476,662       2,612,198  
Other general and administrative expenses   3,811,334       3,411,602     11,085,750       8,787,250  
Total operating expenses   13,177,530       9,038,929     37,938,782       23,506,381  
Income (Loss) from operations   (3,756,759 )     38,190     (11,426,390 )     (259,980 )
Other income              
Interest income   289,967       1,704     313,786       14,597  
Income (Loss) before provision for income taxes   (3,466,792 )     39,894     (11,112,604 )     (245,383 )
Income tax benefit                    
Net Income (Loss) $ (3,466,792 )   $ 39,894   $ (11,112,604 )   $ (245,383 )
Weighted average number of shares outstanding – basic   17,981,184       17,639,346     17,994,288       17,028,762  
Weighted average number of shares outstanding – diluted   17,981,184       18,198,412     17,994,288       17,028,762  
Income (loss) per share – basic $ (0.19 )   $   $ (0.62 )   $ (0.01 )
Income (loss) per share – diluted $ (0.19 )   $   $ (0.62 )   $ (0.01 )

The accompanying notes are an integral part of these condensed consolidated financial statements.


  For Nine Months Ended September 30,
    2022       2021  
Net loss $ (11,112,604 )   $ (245,383 )
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization   1,565,484       1,580,173  
Stock-based compensation   11,476,662       2,362,113  
Stock issued for board service         250,085  
Provision for loss on accounts receivable   132,727       60,000  
Changes in:      
Accounts receivable   6,854,150       (2,921,824 )
Prepaid expenses and other assets   2,199,333       1,891,900  
Accounts payable   393,817       153,395  
Revenue share payable   (1,704,593 )     (1,078,777 )
Accrued expenses and other liabilities   (1,237,839 )     (53,710 )
Operating leases, net   150        
Deferred revenue   (716,693 )     62,610  
Purchase of property and equipment   (64,667 )     (62,565 )
EvinceMed acquisition   (2,000,000 )      
Purchase of short-term investments   (37,468,889 )      
Purchase of intangible assets, including intellectual property rights   (158,321 )     (324,413 )
NET CASH USED IN INVESTING ACTIVITIES   (39,691,877 )     (386,978 )
Proceeds from public offering of common stock, net of offering costs         70,671,536  
Repurchase of common stock   (12,561,571 )      
Proceeds from exercise of stock options   1,050,104       3,805,475  
Payment of contingent consideration         (1,610,813 )
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES   (11,511,467 )     72,866,198  
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   84,681,770       10,516,776  
CASH AND CASH EQUIVALENTS - END OF PERIOD $ 41,329,020     $ 85,056,578  
Cash paid for interest $     $  
Reduction of EvinceMed purchase price for amounts previously paid $ 708,334     $  
Shares issued in connection with acquisition $ 9,374,455     $  
Cash paid for income taxes $     $  

The accompanying notes are an integral part of these condensed consolidated financial statements. 


  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2022       2021     2022       2021  
Net Income (Loss) $ (3,466,792 )   $ 39,894   $ (11,112,604 )   $ (245,383 )
Depreciation and amortization   515,828       526,035     1,565,484       1,580,173  
Stock-based compensation   4,277,241       1,008,007     11,476,662       2,612,198  
Acquisition expense             22,318        
Non-GAAP net income (loss)   1,326,277       1,573,936     1,951,860       3,946,988  
Non-GAAP net income (loss) per share              
Diluted $ 0.07     $ 0.09   $ 0.11     $ 0.22  
Weighted average shares outstanding:              
Diluted   18,088,406       18,198,412     18,169,885       17,555,593  


Primary Logo

Source: OptimizeRx Corporation